Skip to main content
Erschienen in: Journal of Hematology & Oncology 1/2018

Open Access 01.12.2018 | Correction

Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

verfasst von: Xinyang Liu, Shukui Qin, Zhichao Wang, Jianming Xu, Jianping Xiong, Yuxian Bai, Zhehai Wang, Yan Yang, Guoping Sun, Liwei Wang, Leizhen Zheng, Nong Xu, Ying Cheng, Weijian Guo, Hao Yu, Tianshu Liu, Pagona Lagiou, Jin Li

Erschienen in: Journal of Hematology & Oncology | Ausgabe 1/2018

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s13045-017-0521-0.

Correction

The original article [1] contains two errors in Table 2:
1)
The data values in the rows ‘Disease control rate’ and ‘Objective response rate’ and the columns ‘With adverse events’ and ‘Without adverse events’ have mistakenly been interchanged between columns; the values ‘39 (32.77)’ and ‘6 (5.04)’ should be swapped with the values ‘82 (54.67)’ and ‘11 (7.33)’ respectively.
 
2)
The value for the row ‘Median progression-free survival (IQR)’ for the ‘HR/OR’ sub-column should be 0.69, not 0.79.
 
Table 2
Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib
Clinical outcomes
With adverse events (n = 150)
Without adverse events (n = 119)
Unadjusted analysis
Multi-adjusted analysisa
HR/ORb (95% CI)
P valuec
HR/OR (95% CI)
P valued
Median overall survival (IQR), days
169 (96–255)
103 (58–201)
0.67 (0.51,0.88)
0.0039
0.64 (0.48,0.84)
0.001
Median progression-free survival (IQR), days
86.5 (57–150)
62 (41–121)
0.75 (0.58,0.98)
0.0309
0.69 (0.53,0.91)
0.007
Disease control rate, n (%)
82 (54.67)
39 (32.77)
2.47 (1.46,4.21)
< 0.001
2.67 (1.59,4.47)
< 0.001
Objective response rate, n (%)
11 (7.33)
6 (5.04)
1.49 (0.49.5.06)
0.443
1.42 (0.50,4.01)
0.505
Adverse events are defined as hypertension, proteinuria, or hand and foot syndrome in the first 4 weeks of treatment
HR hazard ratio, OR odds ratio, IQR interquartile range
aAdjusted for sex, every 10-year increase in age, number of metastatic sites and ECOG PS
bHR for overall survival and progression survival; OR for disease control rate and objective response rate
cP values calculated from log-rank test for overall survival and progression survival, and chi-square test for disease control rate and objective response rate
dP values calculated from Cox regression for overall survival and progression survival, and logistic regression for disease control rate and objective response rate
As such, the table displayed ahead shows the correct presentation of Table 2 and should be considered instead.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

© Springer Medizin

Bis 11. April 2024 bestellen und im ersten Jahr 50 % sparen!

Literatur
1.
Zurück zum Zitat Liu X, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10:153.CrossRefPubMedPubMedCentral Liu X, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10:153.CrossRefPubMedPubMedCentral
Metadaten
Titel
Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
verfasst von
Xinyang Liu
Shukui Qin
Zhichao Wang
Jianming Xu
Jianping Xiong
Yuxian Bai
Zhehai Wang
Yan Yang
Guoping Sun
Liwei Wang
Leizhen Zheng
Nong Xu
Ying Cheng
Weijian Guo
Hao Yu
Tianshu Liu
Pagona Lagiou
Jin Li
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
Journal of Hematology & Oncology / Ausgabe 1/2018
Elektronische ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-017-0545-5

Weitere Artikel der Ausgabe 1/2018

Journal of Hematology & Oncology 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.